Phaxiam Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.11.24	PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day" (GlobeNewswire)
13.11.24	PHAXIAM Reports Third-Quarter 2024 Financial Information (GlobeNewswire)
08.11.24	Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024 (GlobeNewswire)
04.11.24	PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S. (GlobeNewswire)
10.10.24	Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024 (GlobeNewswire)
09.10.24	PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study (GlobeNewswire)
25.09.24	PHAXIAM Provides Business and Financial Update For the First Half of 2024 (GlobeNewswire)
03.07.24	Monthly information related to total number of voting rights and shares composing the share capital – July 1, 2024 (GlobeNewswire)
28.06.24	Results of the Combined General Meeting of 28 June 2024 (GlobeNewswire)
07.06.24	PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024 (GlobeNewswire)
05.06.24	Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2024 (GlobeNewswire)
15.05.24	PHAXIAM provides Business and Financial Update for the First Quarter of 2024 (GlobeNewswire)
03.05.24	Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024 (GlobeNewswire)
15.04.24	PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus (GlobeNewswire)
09.04.24	Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024 (GlobeNewswire)
05.04.24	PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD) (GlobeNewswire)
20.03.24	PHAXIAM Announces 2023 Full-Year Results and Provides Business Update (GlobeNewswire)
11.03.24	PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market (GlobeNewswire)
05.03.24	Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024 (GlobeNewswire)
20.02.24	PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market (GlobeNewswire)
06.02.24	Monthly information related to total number of voting rights and shares composing the share capital - January 31, 2024 (GlobeNewswire)
18.01.24	PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024 (GlobeNewswire)
03.01.24	Monthly information related to total number of voting rights and shares composing the share capital - December 31, 2023 (GlobeNewswire)
06.12.23	Monthly information related to total number of voting rights and shares composing the share capital - November 30, 2023 (GlobeNewswire)
14.11.23	PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023 (GlobeNewswire)
07.11.23	Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023 (GlobeNewswire)
24.10.23	PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus (GlobeNewswire)
23.10.23	TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation (GlobeNewswire)
23.10.23	Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2023 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Phaxiam Therapeutics

Aktien Top/Flop

Meistgelesene Nachrichten